Literature DB >> 7069864

Growth and cell survival following treatment with estramustine nor-nitrogen mustard, estradiol and testosterone of a human prostatic cancer cell line (DU 145).

B Hartley-Asp, P O Gunnarsson.   

Abstract

Estramustine at concentrations ranging from 3-40 x 10(-6) M inhibited the cell growth and clonogenic survival of a human prostatic carcinoma cell line (DU 145). This cell line was found to be unresponsive to estradiol and testosterone at concentrations ranging from 10(-9) M to 5 x 10(-5) M. Metabolism studies with estramustine showed that only a few per cent of the ester linkage was cleaved during the exposure period. This small amount of metabolism could possibly lead to the release of nor-nitrogen mustard, which was however found not to be as inhibitory as estramustine in this cell line. The results indicate that estramustine per se causes the cell death of hormone unresponsive human prostatic carcinoma cells in cell culture.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7069864     DOI: 10.1016/s0022-5347(17)54057-4

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  12 in total

1.  Presence of oestrogen receptors on target cells and antiproliferative activity of estramustine phosphate: positive correlation for human tumours in vitro.

Authors:  J Pavelić; I Zgradić; K Pavelić
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

2.  Hormone-independent, non-alkylating mechanism of cytotoxicity for estramustine.

Authors:  K D Tew; M E Stearns
Journal:  Urol Res       Date:  1987

Review 3.  Pharmacokinetics and pharmacodynamics of estramustine phosphate.

Authors:  A T Bergenheim; R Henriksson
Journal:  Clin Pharmacokinet       Date:  1998-02       Impact factor: 6.447

Review 4.  Estramustine in malignant glioma.

Authors:  A T Bergenheim; R Henriksson; J M Piepmeier; D Yoshida
Journal:  J Neurooncol       Date:  1996-10       Impact factor: 4.130

5.  Estramustine phosphate reversibly inhibits an early stage during adenovirus replication.

Authors:  E Everitt; H Ekstrand; B Boberg; B Hartley-Asp
Journal:  Arch Virol       Date:  1990       Impact factor: 2.574

6.  The hydrolysis of estramustine phosphate; in vitro studies.

Authors:  O Gunnarsson; S B Andersson; S A Johansson
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1983 Oct-Dec       Impact factor: 2.441

7.  Pharmacokinetics of estramustine phosphate (Estracyt) in prostatic cancer patients.

Authors:  P O Gunnarsson; S B Andersson; S A Johansson; T Nilsson; G Plym-Forshell
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

8.  Dansylated estramustine, a fluorescent probe for studies of estramustine uptake and identification of intracellular targets.

Authors:  M E Stearns; D P Jenkins; K D Tew
Journal:  Proc Natl Acad Sci U S A       Date:  1985-12       Impact factor: 11.205

Review 9.  Estramustine phosphate sodium. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in prostate cancer.

Authors:  C M Perry; D McTavish
Journal:  Drugs Aging       Date:  1995-07       Impact factor: 3.923

10.  Accumulation of estramustine and estromustine in adipose tissue of rats and humans.

Authors:  P O Gunnarsson; S B Andersson; A A Sandberg; M Ellman
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.